I
n the recently published Eighth Joint National Committee (JNC8) guideline for the management of high blood pressure in adults, the threshold for initiation of blood pressurelowering treatment for elderly adults (≥60 years) without chronic kidney disease (CKD) or diabetes mellitus (DM) was raised from 140/90 mm Hg to 150/90 mm Hg. 1 This change resulted in a sizable share of elderly adults in the United States being reclassified as not in need of additional blood pressurelowering treatment. 2 However, the committee was not unanimous in its decision to raise the blood pressure target, particularly because a large proportion of these adults may be at high cardiovascular risk. 3 Indeed, the JNC8 guideline differs from other international guidelines, which recommend a target blood pressure of <140/90 mm Hg for individuals at high cardiovascular risk. 4, 5 Furthermore, a recent meta-analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration demonstrated that blood pressure-lowering results in consistent proportional reductions in vascular risk across risk strata but greater absolute reductions in those at highest absolute risk. 6 There are currently no estimates on what proportion of elderly US adults without CKD or DM are at high 10-year absolute cardiovascular risk (>20%) based on the JNC8 guideline. Accordingly, we conducted this study to determine the absolute 10-year risk of cardiovascular disease in adults reclassified under the JNC8 guideline.
Methods

Study Sample
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional survey conducted by the National Centre for Health Statistics. The survey provides demographic and laboratory data on a representative sample of civilian noninstitutionalized US residents. Participants gave informed consent; NHANES procedures were approved by an institutional review board, and the procedures followed were in accordance with institutional guidelines. This study merged publicly available data sets from the NHANES 2005 to 2012 surveys, and the results are representative for the US population at the midpoint of this time period: January 1, 2009.
Definitions and Measurements
All nonpregnant adults aged 30 to 74 years were included in this study, in accordance with the original age limits used to derive the Framingham risk equation. 7 Participant demographics were based on self-reported age, race, and sex. Blood pressure was measured in the mobile examination center, and details of the procedure are provided elsewhere. 8 Similar to past studies, 9,10 the first blood pressure measurement was used if only 1 measurement was obtained. Subsequent measurements (second, third, and fourth) were averaged according to NHANES guidelines. 11 A percentage of 95.5 of adults had 3 blood pressure measurements, 2.3% had 2 measurements, and 2.2% had 1 measurement. Participant self-reporting was used to determine whether individuals were being treated for hypertension. Specifically, participants answering "yes" to the following question were coded as treated: Are you currently taking medication to lower your blood pressure? Participants with DM were identified based on self-report or an HbA1c level of ≥6.5%. Current smokers were identified based on self-reporting. Furthermore, participants with a history of coronary artery disease, angina, acute myocardial infarction, stroke, and congestive heart failure were identified based on self-reporting and were excluded because the original Framingham cohort did not include adults with prevalent cardiovascular disease.
Renal function was assessed based on the estimated glomerular filtration rate (eGFR), using serum creatinine and the isotope dilution mass spectrometry traceable Modification of Diet in Renal Disease equation, and the albumin-creatinine ratio. Adults with an eGFR ≤60 mL/min per 1.73 m2 or albumin-creatinine ratio of 30 mg/g at any eGFR were considered as having CKD.
1 eGFR values exceeding 200 mL/min per 1.73 m2 were truncated at that level. The eGFR equation was: 175×(serum creatinine) The JNC7 and JNC8 guidelines (prepared by the originally impaneled members) were used to determine which individuals were achieving blood pressure treatment goals. 1, 12 Adults were divided into 3 categories as follows: (1) adults meeting blood pressure goals under both JNC7 and JNC8 were referred to as "at target"; (2) adults above blood pressure goals for JNC7 but reclassified as at target under JNC8 were referred to as "reclassified"; and (3) adults above blood pressure goals for JNC7 and JNC8 were referred to as "above target". It is noteworthy that the reclassified group is made up of adults <60 years with CKD or DM, adults 60 to 74 years without CKD or DM, and adults 60 to 74 years with CKD or DM. These individuals would have been considered as needing treatment (if untreated) or not at target (if treated) by JNC7 and not needing treatment (if untreated) or at target (if treated) by JNC8 (Table 1) . Finally, for adults of age ≥70 years with CKD, the JNC8 guideline did not provide a blood pressure target. For this subgroup, we used a target of 140/90 mm Hg. 13 Results were further stratified by whether adults were currently receiving blood pressure-lowering treatment.
Absolute 10-year risk of cardiovascular events was calculated using the Framingham General Cardiovascular Disease Risk Score. 7 The Framingham risk equation predicts hard vascular events-fatal and nonfatal acute myocardial infarction and stroke-in addition to angina, transient ischemic attack, heart failure, and intermittent claudication. This equation was designed for the use by general practitioners and was chosen for our study given our focus on the management of hypertension in adults without established cardiovascular disease.
The proportion of adults with ≥20% absolute 10-year cardiovascular risk was the primary outcome. Our study also focuses on the reclassified group, with a specific interest on adults 60 to 74 years without CKD or DM.
Statistical Analysis
Variables of interest were assessed for missing data, and none were noted to have >10% of values missing. These missing values were considered missing at random and below the threshold of 10%, unlikely to introduce bias in a complete case analysis.
Statistical analyses were conducted using Stata 13 (Stata Corp, College Station, TX). Sample weights, which account for oversampling, survey nonresponse, and poststratification, were used to derive all estimates. An α level of 0.05 was used as the threshold for statistical significance. Binary variables were summarized using weighted proportions and 95% confidence intervals (95% CIs). Continuous variables were summarized using mean and 95% CIs.
Results
From 2005 to 2012, NHANES included 13 779 adults aged 30 to 74 years without established cardiovascular disease, of which 13 108 participants had blood pressure measurements and 12 963 could be classified for this study. Nine thousand nine hundred thirty-one (80.5%; 95% CI, 79.4%-81.5%) participants were at target, whereas 2118 participants (13.9%; 95% CI, 13.0%-14.8%) were above target and 914 participants (5.7%; 95% CI, 5.1%-6.3%) were reclassified. On the basis of population totals at the midpoint of the 2007 to 2008 year, there were 156.8 million adults between the age of 30 to 74 years, of whom 129.9 million were nonpregnant, without established cardiovascular disease, and had sufficient information to be classified for this study. Using the aforementioned proportion, our estimates correspond to 104.5, 18.1 million, and 7.4 million at target, above target, and reclassified adults (Table 2) .
Using the Framingham risk score, the proportion of adults 60 to 74 years without CKD or DM at ≥20% absolute risk of a cardiovascular event was 44.8%, corresponding to 0.8 million adults in total (Table 3 ). This is compared with 14.0% in adults <60 years with CKD or DM and 47.0% in adults 60 to 74 years with CKD or DM. Notably, the proportion at high risk in the reclassified group was similar in adults 60 to 74 years without CKD or DM mellitus and adults with CKD or diabetes mellitus ( Figure) . The proportion at high cardiovascular risk also remained sizable among adults who were not receiving blood pressure-lowering treatment (Table 3) .
Discussion
In the recent JNC8 guideline, the blood pressure target for elderly adults (≥60 years) without CKD or DM was raised to 150/90 mm Hg, whereas other adults were given the unified blood pressure target of 140/90 mm Hg. Our study demonstrates that 44.8% of these adults 60 to 74 years were at ≥20% absolute cardiovascular risk using the Framingham risk equation. Furthermore, the proportion at high risk remained sizable even among adults who were not currently receiving blood pressure-lowering treatment.
This finding is critical given recent evidence that absolute cardiovascular risk should inform the decision to initiate blood pressure-lowering treatment. In an individual patient data meta-analysis of 11 blood pressure-lowering trials, participants were stratified into 4 quarters based on 5-year absolute risk (cut points for baseline 5-year risk: <11%, 11%-15%, 15%-21%, and >21% from the lowest to the highest risk strata, respectively). 6 The proportional risk reduction in cardiovascular events (stroke, heart attack, heart failure, and cardiovascular death) was consistent across the 4 risk strata, and the absolute risk reduction increased from the lowest absolute risk strata to the highest strata. 6 Accordingly, the number needed to treat to prevent 1 cardiovascular event decreased incrementally from 71 in the lowest risk group to 26 in the highest risk 6 Furthermore, in the high cardiovascular risk group (absolute risk >21%) analyzed in the meta-analysis, a 4 and 8 mm Hg reduction in systolic blood pressure prevented 19 and 37 cardiovascular events per 1000 adults. The generalizability of the meta-analysis was further enhanced by the fact that patients with a wide range of blood pressure were included (mean systolic blood pressure, 158 mm Hg; SD, 21 mm Hg). 14 Similarly, in a comparative modeling analysis of the provision of blood pressure-lowering treatment in the US adult population, the use of blood pressure-lowering treatment based on absolute risk would reduce the number of total cardiovascular events (coronary heart disease and stroke) by 900 000 over 5 years relative to traditional treat to target approach for the initiation of blood pressure-lowering treatment. 15 There is also good evidence on the use of blood pressure lowering from <150 to <140 mm Hg. An earlier meta-analysis of 32 trials by the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC), which included adults with a wide range of baseline systolic blood pressures (128-194 mm Hg), assessed whether the relative risk reduction associated with blood pressure lowering varied by baseline blood pressure. 16 The outcomes of interest were stroke (fatal and nonfatal), coronary heart disease (fatal and nonfatal acute myocardial infarction, and sudden death) and heart failure (causing death or requiring hospitalization). 16 The proportional reduction in vascular risk associated with blood pressure lowering was consistent across baseline blood pressures, irrespective of whether baseline blood pressure was examined as a categorical or continuous variable. 16 These results suggest that blood pressure lowering from <150 to <140 mm Hg in adults 60 to 74 years would produce similar proportional reductions in vascular risk as blood pressure lowering at higher (>150 mm Hg) baseline blood pressures.
Previous researchers have expressed concern about the JNC8 guideline because adults 60 to 74 years without CKD or DM were likely to be at high cardiovascular risk. 3, 17, 18 Our study was conducted to quantify what proportion of reclassified adults were at high cardiovascular risk and to determine the corresponding population estimate for this proportion. Our study cannot determine the clinical implications, if any, of the JNC8 guideline. This would only be possible through a prospective study. Instead, our study and the aforementioned meta-analyses by the BPLTTC suggest that further research in relation to the blood pressure targets specified in the JNC8 guideline may be needed.
The safety of blood pressure lowering toward a threshold of 140/90 mm Hg has also been a key point of concern. However, 2 trials, Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patient (JATOS) and valsartan in elderly isolated systolic hypertension (VALISH), provide evidence that lowering blood pressure toward this threshold does not result in a surplus of adverse events.
3,19,20 JATOS randomized 4418 adults aged 65 to 85 years, whereas VALISH randomized 3260 adults 70 to 85 years.
19,20 Both trials set systolic blood pressure goals to lower than 140 mm Hg for the highintensity group and 140 to 160 and 140 to 149 mm Hg for the low-intensity group, respectively. 19, 20 In JATOS, 1.6% of participants in both groups withdrew because of adverse events, and a similar pattern was noted for VALISH: 18.2% in the high-intensity group and 17.9% in the low-intensity group. 19, 20 Finally, the blood pressure target was also raised from 130/80 to 140/90 mm Hg for adults <60 years with CKD or DM. This change in the JNC8 guideline is consistent with international guidelines 5 and randomized controlled trials demonstrating limited benefit from blood pressure lowering to <130/80 mm Hg in adults with CKD. 21 However, additional study is required to determine whether more intensive blood pressure lowering may be more appropriate for adults with proteinuric kidney disease.
The key strength of our study is the use of a nationally representative data set, which allows our results to be generalizable to adults aged 30 to 74 years in the United States. However, our study also has limitations. First, we used blood pressure measured through NHANES and some participants had only a single blood pressure measurement. As well, all blood pressure measurements were collected at a single point in time and we lacked any trends in each individual's blood pressure measurements. Similarly, diagnosis of CKD was based on a single serum creatinine measurement. These factors could have resulted in random misclassification of adults. Finally, the Framingham risk equation may underestimate risk in adults with CKD.
Perspective
Our study demonstrates that 44.8% of reclassified adults 60 to 74 years of age were at ≥20% absolute cardiovascular risk, corresponding to 0.8 million adults. Additional research is needed to determine how practice patterns change after the release of the JNC8 guideline. What Is New?
• In the Eighth Joint National Committee guideline on hypertension, the threshold for initiation of blood pressure-lowering treatment for elderly adults (≥60 years) without chronic kidney disease or diabetes mellitus was raised from 140/90 to 150/90 mm Hg. However, the committee was not unanimous in this decision, particularly because a large proportion of adults may be at high cardiovascular risk. We sought to determine the predicted absolute 10-year risk of cardiovascular disease in adults based on the Seventh Joint National Committee and Eighth Joint National Committee guidelines through an analysis of the National Health and Nutrition Examination Survey (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) .
What Is Relevant?
• Hypertension is a leading cause of morbidity and mortality in the United States. The control of hypertension is a public health priority, and clinical guidelines are important in public health efforts to improve the management of hypertension. It is, therefore, critical to understand the general and clinical characteristics of adults that are recommended (or not recommended) for treatment under clinical guidelines.
Summary
From 2005 to 2012, the National Health and Nutrition Examination Survey included 12 963 adults aged 30 to 74 years with blood pressure measurements, of which 914 adults were reclassified based on the guideline. Using the Framingham risk score, the proportion of reclassified adults aged 60 to 74 years without CKD or diabetes mellitus at ≥20% absolute risk of a cardiovascular event was 44.8%, corresponding to 0.8 million adults in total. The proportion at high cardiovascular risk remained sizable among adults who were not receiving blood pressure-lowering treatment. 
